What is THCP? The Most Potent Cannabinoid - Complete Guide 2026

What is THCP?

THCP (Δ9-Tetrahydrocannabiphorol, also written Δ9-THCP) is a phytogenic cannabinoid — that is, of plant origin — first identified in the Cannabis sativa plant in 2019. It belongs to the same chemical family as THC (Δ9-Tetrahydrocannabinol), but presents a fundamental structural difference that makes it radically more potent: an alkyl side chain with seven carbon atoms instead of the five found in THC.

This difference may seem trivial on paper, but in terms of interaction with the human endocannabinoid system, it represents an enormous qualitative change. Published studies show that THCP binds to cannabinoid CB1 receptors with approximately 33 times greater affinity than standard THC. At CB2 receptors, the difference is even more pronounced: up to 5–10 times greater than THC.

Prior to the discovery of THCP, THC with a five-carbon alkyl chain was considered the most psychoactively active natural cannabinoid. THCP changes that equation: its natural presence in the plant — albeit in trace quantities — suggests that part of the variability in cannabis effects between different varieties could be explained, at least partially, by the levels of THCP present.

Full Name and Nomenclature

The full name of THCP is (-)-trans-Δ9-tetrahydrocannabiphorol. In the scientific literature it also appears as:

• Δ9-THCP
• (-)-trans-Δ9-THCP
• Tetrahydrocannabiphorol
• THCP-C7 (referring to the 7-carbon chain)

It should not be confused with synthetic THCP produced in the laboratory for research purposes, although they are chemically identical. Natural THCP exists in the plant; synthetic THCP is produced for experiments or for the cannabinoid market.

The Discovery: Italy, 2019

THCP was discovered by a team of Italian researchers from the Università degli Studi di Modena e Reggio Emilia, with the participation of the Istituto Chimico Farmaceutico Militare (ICFM) of Florence. The lead author of the study was Cinzia Citti, together with Pasquale Linciano, Fabio Russo and other collaborators.

The study was published in December 2019 in the journal Scientific Reports, an open-access publication of the Nature Publishing Group. The original title: "(-)-trans-Δ9-tetrahydrocannabiphorol and (-)-trans-Δ9-tetrahydrocannabiorcol: cannabis constituents with a seven-term and a one-term alkyl side chain".

The Cannabis Variety Analysed

THCP was isolated from an Italian medicinal cannabis variety called FM2, produced and distributed by the Istituto Chimico Farmaceutico Militare (ICFM) of Florence. This variety is one of the few cannabis flowers produced under state control in Italy for medical use.

The fact that the discovery was made using controlled medicinal cannabis is significant: it reinforces the idea that THCP is a natural component of the plant, not an artificial additive, even though it is present at very low concentrations (around 0.0001% of dry weight in unselected varieties).

Analytical Technique Used

The researchers used a combination of high-resolution mass spectrometry (HRMS) and nuclear magnetic resonance (NMR) to structurally identify and characterise THCP. State-of-the-art analytical techniques were required because the concentration of THCP in the plant is extremely low, which had prevented its detection with available instruments during decades of cannabis research.

THCP Chemistry: Why It's Different

To understand what makes THCP special, it is necessary to briefly understand the structure of cannabinoids and how small molecular differences produce radically different effects.

The THC Homologue Family

THC and its homologues are molecules that share the same basic chemical backbone — a dibenzopyran ring combined with a side chain — but differ in the length of that alkyl side chain. In chemistry, compounds that have the same base structure but differ in the number of repeating units of a chain are called homologues.

The THC homologue family includes:

The relationship between chain length and receptor affinity is not indefinitely linear: studies show that maximum affinity is reached at around 6–8 carbons, after which the molecule becomes too bulky to fit correctly into the receptor.

Why Do 2 Extra Carbons Make Such a Difference?

The answer lies in how the cannabinoid docks into the CB1 receptor. The CB1 receptor is a transmembrane protein with a hydrophobic binding pocket — an internal cavity that the cannabinoid must occupy to activate the receptor. The alkyl side chain of the cannabinoid acts as a "hook" that inserts into a lipophilic region of this pocket.

A 5-carbon chain (THC) fits correctly into this pocket. A 7-carbon chain (THCP) does so more deeply and with greater contact surface area, resulting in:

• Greater binding energy to the receptor (lower Ki)
• Longer residence time in the receptor before dissociation
• More intense activation of the intracellular signal
• More potent effects at the same molar dose

How Much More Potent is THCP?

The figure of "33 times more potent" is one of the most cited in relation to THCP, but it requires context to be interpreted correctly.

What "33 Times More Potent" Actually Means

This figure refers specifically to the binding affinity for the CB1 receptor measured in radioligand competition assays in vitro. It does not mean that consuming THCP produces subjective effects 33 times more intense than THC. Perceived potency depends on many additional factors:

• Bioavailability: how much THCP reaches the bloodstream and the brain depending on the route of administration
• Metabolism: how the body converts THCP into active or inactive metabolites
• Intrinsic efficacy: the extent to which THCP acts as a full versus partial agonist at the receptor
• Individual tolerance: sensitivity of each person's endocannabinoid system
• Receptor distribution: CB1 density in different brain areas

That said, THCP's greater receptor binding affinity does translate into more potent effects at equivalent doses. In the 2019 study, experiments in mice showed that THCP produced the four classic effects of THC — the cannabinoid tetrad — at significantly lower doses:

The Cannabinoid Tetrad

In animal models, potent cannabinoids produce what is known as the cannabinoid tetrad: four classic effects used as a marker of CB1 activity:

Effects of THCP on the Body

The human effects of THCP have not been studied in controlled clinical trials up to 2026 — at least not in studies published in indexed journals. Everything we know about effects in humans comes from three sources: animal studies, analogy with THC (given that it acts on the same receptors), and user reports (with all the methodological limitations that entails).

Expected Effects Based on Analogy with THC

Since THCP acts on the same receptors as THC — CB1 in the central nervous system and CB2 in the immune system — it is expected to produce qualitatively similar but quantitatively more intense effects at equivalent doses:

• Euphoria and intoxication: the typical psychoactive effect of cannabis, likely more pronounced
• Alteration of sensory perception: auditory, visual, tactile
• Muscle relaxation: via CB1 activation in the motor system
• Analgesia: reduction in pain perception
• Appetite stimulation (the munchies): via the hypothalamus
• Initial tachycardia: transient increase in heart rate
• Anxiety and paranoia if the dose exceeds the individual threshold
• Sedation: especially at high doses

Duration of Effects

Although no specific human clinical data exist, THCP's greater CB1 receptor binding affinity suggests it could have a longer duration of action than THC. A cannabinoid that binds more strongly to the receptor takes longer to dissociate, prolonging the effect.

Users who have reported experiences with THCP describe effects lasting 3 to 5 hours when consumed by vaporisation, significantly longer than the typical 2–3 hours for vaporised THC. Via the oral route (oils, edibles), effects could extend considerably further.

The Endocannabinoid System and THCP

To understand why THCP has such a potent effect, it is essential to understand how the endocannabinoid system (ECS) works.

What is the Endocannabinoid System?

The ECS is a neuronal communication system present in all vertebrates. It was discovered in the 1990s precisely as a result of research into how THC produces its effects. It is composed of:

• Endogenous endocannabinoids: anandamide (AEA) and 2-arachidonoylglycerol (2-AG), produced by the body itself
• Cannabinoid receptors: CB1 (primarily in the CNS) and CB2 (primarily in immune tissue)
• Synthesis and degradation enzymes: FAAH (degrades anandamide), MAGL (degrades 2-AG)

The primary function of the ECS is retrograde synaptic modulation: postsynaptic neurons release endocannabinoids that "backwards" modulate neurotransmitter release from the presynaptic neuron. This regulates neuronal excitability, pain, emotional states, appetite, sleep and memory.

CB1 and CB2: Where They Are and What They Do

THCP at the CB1 Receptor

As a high-affinity CB1 agonist, THCP produces more intense and prolonged activation of the intracellular signalling that follows receptor-ligand binding. This signalling includes inhibition of adenylyl cyclase (reduction of cAMP), activation of potassium channels (neuronal hyperpolarisation) and inhibition of voltage-gated calcium channels.

The net result is a more pronounced inhibition of neuronal activity in brain regions where CB1 is most densely expressed, which translates into the subjective and physiological effects described above.

THCP vs THC, HHC, CBD and Other Cannabinoids

The cannabinoid market in Europe has seen a proliferation of compounds in recent years, many of them with confusingly similar names. This table compares THCP with the most relevant cannabinoids:

THCP vs THC: Same Family, Different Scale

THCP and Δ9-THC are essentially the same type of molecule — plant-derived CB1 agonists — but with radically different potencies. The most relevant practical differences:

• Active doses: THCP requires much lower doses to produce equivalent effects
• Duration: THCP effects are likely more prolonged
• Overdose risk: greater with THCP due to the narrow margin between a "recreational" dose and an overwhelming one
• Availability in the plant: THC is present at 10–30% in current varieties; THCP at trace levels of 0.0001% or less
• Legal status: THC is explicitly prohibited in almost all of the EU; THCP often falls into a grey area as it is not specifically named

THCP vs HHC: Two Routes to the Same Receptor

HHC 'hexahydrocannabinol) gained popularity in Europe from 2022 as an alternative to THC in countries where Δ9-THC is prohibited. It shares with THCP the fact of acting on CB1, but there are important differences:

• HHC is produced primarily by hydrogenation of CBD (semi-synthetic); THCP exists naturally although it is also produced synthetically
• HHC potency is estimated at 70–80% of THC; THCP exceeds THC by 33 times
• HHC has two isomers (9α and 9β) with different potencies; THCP has a fixed configuration

How is THCP Obtained?

Given that THCP is present in the cannabis plant at extremely low concentrations (fractions of 0.01%), direct extraction from plant material is not commercially viable. THCP products circulating on the market use two methods:

1. Chemical Synthesis from CBD

The most common method is semi-synthetic synthesis from isolated CBD. CBD can be converted into THC (and its homologues, including THCP) via acid cyclisation reactions. The process requires:

• Isolated CBD from hemp (industrial cannabis with ≤0.3% THC)
• Acid catalysts (BF₃, p-toluenesulfonic acid)
• 7-carbon alkyl chain precursors
• Distillation and purification of the final product

2. Extraction and Concentration from Specialised Plant Material

Some cannabis varieties selected for high homologue content may have somewhat higher concentrations of THCP. However, even in the richest varieties, the percentage rarely exceeds 0.01%, making direct extraction unviable at industrial scale without processing enormous quantities of plant material.

Commercial Formats

In the European market — primarily in online shops and head shops — THCP is found in the following formats:

Legal Status of THCP in Europe (2026)

The legal status of THCP in Europe is complex and varies significantly between countries. The reason: when the laws controlling cannabis and its derivatives were drafted, THCP had not yet been discovered, so most legislation does not name it explicitly. This creates a "grey area" that each country is interpreting differently.

General Regulatory Framework

The main mechanism by which THCP could be prohibited in most European countries is through analogue clauses or "similar substances" provisions that extend the prohibition on THC to compounds with a similar chemical structure. Some countries also maintain lists of new psychoactive substances (NPS) that are updated periodically.

Regulatory Trends in Europe

The general trend in the EU is towards more explicit regulation of psychoactive cannabinoids, including THC analogues. The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA / EUDA since 2023) has included THCP and other synthetic/semi-synthetic cannabinoids in its early warning reports. It is foreseeable that within the next few years more European countries will incorporate THCP onto their controlled substances lists.

Is THCP Safe? Risks and Precautions

This is probably the most important question and also the most difficult to answer rigorously, given the current state of research.

What We Know (Real Science)

Human safety data for THCP are virtually non-existent in peer-reviewed scientific literature. What we have are:

• In vitro studies: receptor binding profile in brain tissue
• In vivo studies in mice: cannabinoid tetrad, with no obvious signs of acute toxicity at the doses tested
• Analogy with THC: given that it acts on the same receptors, the THC risk profile serves as a reference, although amplified

Specific Risks of THCP

Higher-Risk Populations

• Adolescents and young people: greater vulnerability of the developing brain to psychoactive cannabinoids
• People with a history of psychosis: potent CB1 agonists can precipitate psychotic episodes
• Pregnant and breastfeeding women: cannabinoids cross the placental barrier and are excreted in breast milk
• People with cardiovascular conditions: tachycardia and transient hypotension
• People on medication: risk of drug interactions

THCP and Medical Cannabis

THCP's high potency presents both opportunities and challenges from a medicinal standpoint. The researchers who discovered it suggested it could have relevant therapeutic applications, although research remains at very early stages.

Areas of Therapeutic Interest

By analogy with THC and given its pharmacological profile, the areas where THCP could be investigated in the future include:

• Severe chronic pain: high potency could be useful in patients non-responsive to THC or requiring very low doses of active compound
• Treatment of insomnia: potent cannabinoids have sedative properties
• Refractory nausea and vomiting: especially in chemotherapy
• Severe spasticity: by analogy with the muscle-relaxing effects of THC

The Therapeutic Index Problem

One of the most important challenges for the medicinal development of THCP is its potential narrow therapeutic index. The therapeutic index measures the ratio between the effective dose (producing the desired effect) and the toxic dose (producing serious adverse effects). A narrow therapeutic index means therapeutic doses are close to those that produce unwanted effects.

With THCP, given that active doses are very low, any small variation in dosing — due to differences in individual metabolism, route of administration or product formulation — can mean the difference between efficacy and toxicity.

What Published Studies Say

The scientific evidence on THCP is still limited but genuine. Below are the most relevant studies published up to 2026:

Foundational Study (2019)

Cannabiphorol (THCP) discovery and characterisation
Citti C, Linciano P, Russo F, et al. Scientific Reports (Nature). 2019.

The study that changed everything. Identification of THCP in FM2 cannabis via HRMS and NMR. In vitro receptor binding assays (Ki CB1 = 1.2 nM vs 40.7 nM for THC). In vivo studies in mice: cannabinoid tetrad, analgesia, hypothermia and catalepsy at 2.5 mg/kg. First study to demonstrate the natural existence of a phytogenic cannabinoid with a 7-carbon alkyl chain.

Surveillance and Toxicology Studies (2021–2023)

Several reports from forensic laboratories and European drug safety agencies have identified THCP in market products:

• French Gendarmerie Forensic Institute (IRCGN): detection in hemp flowers and vape products
• EMCDDA Early Warning System: alerts on products containing THCP and their harm potential
• Austrian forensic laboratories: cases of intoxication attributed to THCP

Systematic Reviews on Emerging Psychoactive Cannabinoids (2022–2025)

Several reviews in journals such as Drug and Alcohol Dependence, Frontiers in Psychiatry and Current Neuropharmacology have addressed the landscape of novel psychoactive cannabinoids, including THCP, albeit without their own clinical data given the lack of research in humans.

THCP Pharmacokinetics: Absorption, Distribution and Metabolism

Pharmacokinetics studies what the body does with a substance: how it absorbs it, how it distributes it through tissues, how it metabolises it and how it eliminates it. There are no specific published data on THCP pharmacokinetics in humans, but reasonable extrapolations can be made from what we know about THC, given that they share the same structural core.

Routes of Administration and Bioavailability

The route of administration determines how much active compound reaches the bloodstream and how quickly:

The low oral bioavailability of THC — and presumably of THCP — is due to the hepatic first-pass effect: a large proportion of the cannabinoid is metabolised in the liver before reaching the brain. However, when THC is metabolised in the liver it produces 11-OH-THC, an active metabolite that is more polar and potentially better able to cross the blood-brain barrier. An analogous process could occur with THCP, which would explain why edibles tend to produce more potent and unpredictable effects than inhalation.

Tissue Distribution

Cannabinoids are highly lipophilic molecules: they accumulate in fatty tissues. THCP, with its 7-carbon side chain more hydrophobic than that of THC, could have even greater affinity for fatty tissues, which would imply:

• Greater volume of distribution: more compound sequestered in peripheral tissues
• Slow release from adipose deposits, prolonging the perceived effect
• Accumulation with repeated use in adipose tissue, potentially detectable in urine for longer periods

Metabolism and Elimination

THC is metabolised primarily by the CYP2C9 and CYP3A4 enzymes of the cytochrome P450 system, producing 11-OH-THC (active) and subsequently 11-COOH-THC (inactive), the main metabolite detected by urine tests. THCP presumably follows similar metabolic pathways, although the specific metabolites have not been characterised in detail.

The elimination half-life of THC is 20–57 hours in occasional users and up to 13 days in chronic users, due to accumulation in adipose tissue. THCP could have an even longer half-life due to its greater lipophilicity. This has important implications for drug testing: THCP may be detectable for longer periods than THC.

How to Identify and Evaluate THCP Products

If you are in a country where THCP sits in a legal grey area and you are considering products containing it, evaluating product quality and safety is critical. The unregulated market has serious problems with inaccurate labelling and contamination.

Warning Signs in THCP Products

What to Look for in a COA (Certificate of Analysis)

A third-party certificate of analysis is the minimum level of transparency you should demand. It must include:

• Name and address of the accredited laboratory that performed the analysis
• Lot number of the product analysed
• Complete cannabinoid profile (not just THCP, but also residual THC, CBD, CBN, etc.)
• Pesticide and heavy metal analysis
• Solvent residue analysis (especially if the THCP is semi-synthetic)
• Date of analysis (no more than 12 months old)

The Labelling Issue

One of the most documented problems in the emerging cannabinoid market is the discrepancy between the declared label content and the actual product content. Independent laboratory studies of HHC and Δ8-THC products have found variations of up to ±50% between declared and actual content. With THCP, given its greater potency, this variation can have far more significant consequences for the user.

Harm Reduction if Consuming THCP

If, despite the risks described, a person decides to consume THCP, the following harm reduction practices are especially important:

• Start with minimum doses: divide the dose; wait to assess the effect before repeating
• Never alone: always have a trusted person present, especially during first experiences
• Safe environment: familiar, comfortable surroundings, with no commitments requiring driving or other responsibilities
• Avoid the oral route for first-time use: inhalation allows better control of onset and intensity
• Do not mix: avoid alcohol, benzodiazepines or other psychoactive substances
• Hydration: drink water; xerostomia (dry mouth) is common with cannabinoids
• Know your source: only products with a verifiable COA from accredited laboratories

The Future of THCP: Research, Regulation and Market

THCP has only been known to the scientific community for six years. In that time it has gone from being an academic curiosity published in a sientific journal to being commercially available in dozens of European online shops. This speed of commercialisation, completely disconnected from the pace of scientific research and regulation, is characteristic of the current landscape of emerging cannabinoids.

What Research is Needed?

To establish a genuine safety and efficacy profile for THCP in humans, the following would be required:

• Pharmacokinetic studies in healthy volunteers: characterising absorption, distribution, metabolism and elimination in real humans
• Tolerability trials: determining the maximum tolerated dose and adverse effect profile across different dose ranges
• Drug interaction studies: especially with widely used medications (anticoagulants, antidepressants, antiepileptics)
• Assessment of abuse and dependence potential: self-administration and withdrawal studies
• Phase I and II clinical trials if any promising therapeutic indication is confirmed

Regulatory Trends

The European Medicines Agency (EMA) and EUDA (formerly EMCDDA) are closely monitoring the proliferation of emerging psychoactive cannabinoids. Several member states have begun procedures to include THCP and other analogues on their controlled substances lists. The experience with HHC in France — banned by ministerial decree in 2023 — and in other countries suggests THCP could follow a similar trajectory in most European states within the next one to three years.

For the legal cannabis market (where it exists, such as in Germany), THCP has no place under current regulation: the German CanG, which since 2024 permits personal possession and cultivation of cannabis, does not include THC analogues or semi-synthetic cannabinoids. The only clear legal pathway for THCP would be as a prescription medicine, which would require completing the full EMA regulatory process.

Frequently Asked Questions about THCP